USA — Insulet has acquired technology from Automated Glucose Control (AGC) for US$25 million, marking the company’s second purchase in as many days related to automated insulin delivery.
Insulet and AGC had a longstanding partnership since 2016, with Insulet obtaining licensing rights to AGC’s patents and intellectual property, which included an algorithm that connects insulin pumps and continuous glucose monitors to create an artificial pancreas system.
Insulet utilized this algorithm during the development of the Omnipod 5 insulin pump, which received FDA approval and began commercial distribution last year.
This system automates insulin delivery from the pump based on blood sugar readings from the connected CGM.
This technology was utilized in the development of Insulet’s Omnipod 5 insulin pump, which received FDA clearance and was released last year.
Insulet expressed satisfaction with its relationship with AGC and looks forward to furthering advancements in automated insulin delivery technology.
The purchase includes the University of California, Santa Barbara (UCSB) license and other IPs owned by AGC.
Insulet’s purchase from Bigfoot Biomedical, which happened the day prior, will be used to enhance its tubeless pump system’s algorithm capabilities, while Bigfoot will focus on its “smart” pen cap devices.
The heart of both the initial licensing agreement and the recent US$25 million deal is an algorithm that connects insulin pumps and continuous glucose monitors (CGM) to create an artificial pancreas system.
Bigfoot will use the payment to concentrate on its “smart” pen cap devices while transferring its additional patents to Insulet.
Bigfoot’s main technology is an artificial intelligence algorithm that analyzes CGM data to recommend insulin dosages throughout the day, which is fitted onto a disposable insulin pen cap.
Insulet anticipates that the newly acquired technology will help strengthen the algorithms powering its tubeless pump system.
Omnipod 5’s latest version is programmed to receive glucose readings from a connected Dexcom CGM and use them to automatically adjust insulin delivery.
This entire process aims to be practically hands-free for users, although it can be monitored through a linked controller or their smartphone.
Jennifer Schneider, M.D., and Thomas Peyser, Ph.D., co-founders of AGC, acted as consultants throughout the development process.